# Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease

> **NCT04006288** · PHASE4 · COMPLETED · sponsor: **University of Florida** · enrollment: 90 (actual)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** Clopidogrel
- **DRUG:** Prasugrel
- **DRUG:** ticagrelor
- **DRUG:** aspirin
- **DRUG:** rivaroxaban

## Key facts

- **NCT ID:** NCT04006288
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-06
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-05-16
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2023-04-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04006288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04006288, "Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT04006288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*